IDH2 and acute myeloid leukemia: In this perspective, the clinical benefit of adding ivosidenib or enasidenib to induction, consolidation and maintenance therapy for patients with newly diagnosed IDH1/IDH2-mutated AML is being evaluated in a phase 3, double-blind, randomized, placebo-controlled study presently recruiting (ClinicalTrials.gov NCT03839771).